
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte Inc has demonstrated strong financial performance, with a non-GAAP operating margin of 28.8%, reflecting a significant year-over-year increase of 830 basis points. The company's genomic test volume reached approximately 45,888, showing an 18% growth, while testing revenue surged to $127.8 million, marking a 17% increase in 3Q25. Additionally, management has raised its guidance for adjusted EBITDA margin for 2025 to approximately 25.0%, indicating robust improvement from previous years and a positive outlook for sustained growth.
Bears say
Veracyte Inc. faces significant risks that could negatively impact its financial performance, including weaker-than-expected sales for its Decipher and Afirma tests, deteriorating operating margins, and unfavorable free cash flow projections. Revenue per test showed a decline to $2,784 in 3Q25, suggesting challenges in maintaining pricing power, while management's adjusted EBITDA margin guidance for 2026 has decreased to approximately 25% from 27.5% in the previous year. Additionally, the company's genomic test volume growth has slowed, with a projected bear case scenario indicating sustained revenue growth at less than 13%, driven by anticipated underperformance in both line of products and overall margin pressures.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares